

Albert Wiegman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/585547/publications.pdf>

Version: 2024-02-01

58
papers

8,089
citations

159585

30
h-index

161849

54
g-index

59
all docs

59
docs citations

59
times ranked

5231
citing authors

#	ARTICLE	IF	CITATIONS
1	Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 779-792.	1.8	47
2	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728.	13.7	69
3	Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2022, 16, 128-142.	1.5	7
4	Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1361-1368.	1.8	20
5	Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia. <i>BMC Pediatrics</i> , 2022, 22, 131.	1.7	2
6	Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic. <i>Atherosclerosis</i> , 2022, 349, 227-232.	0.8	39
7	Screening in children for familial hypercholesterolaemia: start now. <i>European Heart Journal</i> , 2022, 43, 3209-3212.	2.2	36
8	Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. <i>Atherosclerosis</i> , 2021, 319, 108-117.	0.8	18
9	Marked plaque regression in homozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 327, 13-17.	0.8	35
10	Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands. <i>Genes</i> , 2021, 12, 1168.	2.4	12
11	Advances in familial hypercholesterolaemia in children. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 652-661.	5.6	17
12	Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. <i>Atherosclerosis</i> , 2020, 292, 178-187.	0.8	41
13	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 1317-1327.	27.0	108
14	Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?. <i>Atherosclerosis</i> , 2020, 304, 1-8.	0.8	36
15	Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. <i>Atherosclerosis</i> , 2020, 299, 24-31.	0.8	20
16	20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2019, 381, 1547-1556.	27.0	405
17	Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 285, 87-92.	0.8	14
18	Statins for children with familial hypercholesterolemia. <i>The Cochrane Library</i> , 2019, 2019, .	2.8	40

#	ARTICLE	IF	CITATIONS
19	The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 272-278.	1.5	7
20	Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review. <i>Journal of Clinical Lipidology</i> , 2019, 13, 31-39.	1.5	25
21	Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 422-429.	2.0	17
22	Regional assessment of carotid artery pulse wave velocity using compressed sensing accelerated high temporal resolution 2D CINE phase contrast cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 86.	3.3	17
23	Screening for lysosomal acid lipase deficiency: A retrospective data mining study and evaluation of screening criteria. <i>Atherosclerosis</i> , 2018, 278, 174-179.	0.8	2
24	Lipid Screening, Action, and Follow-up in Children and Adolescents. <i>Current Cardiology Reports</i> , 2018, 20, 80.	2.9	15
25	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1199-1207.	1.5	24
26	Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 507-514.	1.5	19
27	Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 136, 359-366.	1.6	84
28	Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1162-1170.	2.8	42
29	Knowns and unknowns in the care of pediatric familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2017, 58, 1765-1776.	4.2	39
30	Statins for children with familial hypercholesterolemia. <i>The Cochrane Library</i> , 2017, 7, CD006401.	2.8	94
31	Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 919-921.	3.1	2
32	Children with hypercholesterolemia of unknown cause: Value of genetic risk scores. <i>Journal of Clinical Lipidology</i> , 2016, 10, 851-859.	1.5	21
33	Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1462-1469.	1.5	25
34	Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 251, 263-265.	0.8	27
35	Statin Initiation During Childhood in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 455-456.	2.8	34
36	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	1.8	60

#	ARTICLE	IF	CITATIONS
37	Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood. <i>Atherosclerosis</i> , 2015, 241, 427-432.	0.8	21
38	Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. <i>Journal of Clinical Lipidology</i> , 2015, 9, 741-750.	1.5	42
39	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	2.2	644
40	Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. <i>Journal of Pediatrics</i> , 2015, 167, 338-343.e5.	1.8	40
41	Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries. <i>Clinical Chemistry</i> , 2015, 61, 231-238.	3.2	166
42	Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. <i>European Heart Journal</i> , 2015, 36, 560-565.	2.2	366
43	Statins for children with familial hypercholesterolemia. , 2014, , CD006401.		26
44	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	2.2	835
45	Ten-Year Follow-up After Initiation of Statin Therapy in Children With Familial Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1055.	7.4	143
46	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	1.5	98
47	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	1.7	316
48	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	2.2	2,132
49	Familial Hypercholesterolemia: Advances in Understanding the Early Natural History. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 562-566.	2.0	0
50	Molecular Basis of Autosomal Dominant Hypercholesterolemia. <i>Circulation</i> , 2011, 123, 1167-1173.	1.6	91
51	Statin Treatment in Children With Familial Hypercholesterolemia. <i>Circulation</i> , 2007, 116, 664-668.	1.6	252
52	Paraoxonase genotype and carotid intima-media thickness in children with familial hypercholesterolemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 464-466.	2.8	0
53	Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. <i>Atherosclerosis</i> , 2005, 180, 93-99.	0.8	36
54	Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 331.	7.4	534

#	ARTICLE	IF	CITATIONS
55	Measurement of Arterial Wall Thickness as a Surrogate Marker for Atherosclerosis. <i>Circulation</i> , 2004, 109, III33-8.	1.6	399
56	Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. <i>Lancet</i> , The, 2004, 363, 369-370.	13.7	282
57	The Apolipoprotein μ 4 Allele Confers Additional Risk in Children with Familial Hypercholesterolemia. <i>Pediatric Research</i> , 2003, 53, 1008-1012.	2.3	15
58	Family History and Cardiovascular Risk in Familial Hypercholesterolemia. <i>Circulation</i> , 2003, 107, 1473-1478.	1.6	131